Ms. Hirano is our Senior Vice President, Regulatory Affairs and has over 20 years of regulatory affairs in the biopharmaceutical industry. She joined the Company as Vice President, Regulatory Affairs in January, 2019. From April, 2017 through December, 2018, Ms. Hirano served as Head of Regulatory Affairs and Quality at the Company in a consulting capacity.
Prior to this, she was an independent regulatory consultant since April, 2010, providing regulatory affairs, project management, and clinical operations expertise to biopharmaceutical and biosimilar companies. Her experience encompasses the development of pharmaceuticals, biologics, and drug-device combination products for the treatment of oncology, cardiovascular, neurology, pulmonary/allergy, and endocrine/metabolic diseases. Prior to 2010, she held various positions of increasing responsibility at the Company, Titan Pharmaceuticals, Inc., PRTM (now PWC), CV Therapeutics, Inc. (acquired by Gilead), and Matrix Pharmaceutical, Inc. (acquired by Chiron Corp). She has also been the coordinator of the Bay Area Compliance Discussion Group since 1998. She has been a Director at The Big C Society since April 2014. She earned a Bachelor's degree in physical education from the University of California, Berkeley, and Master of Public Health degree from San Jose State University.
What is Patricia C. Hirano's net worth?
The estimated net worth of Patricia C. Hirano is at least $700.05 thousand as of July 1st, 2025. Ms. Hirano owns 13,206 shares of Soleno Therapeutics stock worth more than $700,050 as of July 10th. This net worth estimate does not reflect any other assets that Ms. Hirano may own. Learn More about Patricia C. Hirano's net worth.
How do I contact Patricia C. Hirano?
Has Patricia C. Hirano been buying or selling shares of Soleno Therapeutics?
Patricia C. Hirano has not been actively trading shares of Soleno Therapeutics during the last quarter. Most recently, Patricia C. Hirano sold 3,830 shares of the business's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $82.76, for a transaction totalling $316,970.80. Following the completion of the sale, the insider now directly owns 13,206 shares of the company's stock, valued at $1,092,928.56. Learn More on Patricia C. Hirano's trading history.
Who are Soleno Therapeutics' active insiders?